IMV Inc. (NASDAQ:IMV) Q1 2019 Earnings Conference Call Transcript
May 10, 2019 • 08:00 am ET
Good day, ladies and gentlemen, and welcome to the IMV's First Quarter Results Conference Call. At this time, all participants are in a listen-only mode. Later, we'll conduct a question-and-answer session, and instructions will be given at that time. (Operator Instructions) As a reminder, this call may be recorded.
I would now like to turn the call over to, Pierre Labbe, CFO. You may begin.
Thank you, Michelle. Thanks, everyone, for joining the call this morning. I'm Pierre Labbe, CFO at IMV. Joining me today on this call, we have Fred Ors, our CEO. And also, during the Q&A session, Gabriela Rosu, our Chief Medical Officer, will be available to answer your question.
Before we begin, I would like to remind you that except for historical information, this presentation contains forward-looking statements, which reflects IMV's current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause IMV's actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly filings and also in our annual information form. The forward-looking statements in this presentation are also based on a number of assumptions, which may prove to be incorrect.
Forward-looking statements contained in this presentation represent views only as of the date of this presentation, and are presented for the purpose of assisting potential investors in understanding IMV's business, and may not be appropriate for other purposes. IMV does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation.
Investors are cautioned not to rely on these forward-looking statements, and are encouraged to read IMV's continuous disclosure documents, including its current annual information form as well as its audited annual consolidated financial statements, which are available on SEDAR at sedar.com and on EDGAR at sec.gov/edgar.
I will now turn the call over to, Fred Ors, our CEO. Fred?
Thank you, Pierre, and good morning, everyone. I will start with an update on our clinical development and other business highlights, and then I will hand it back to Pierre for a review of our financial results for the quarter.
Our progress in this quarter includes promising initial data from the Phase II cohort of the DeCidE1 clinical study, underscoring the potential of our products, DPX-Survivac as a monotherapy, receiving in collaboration with le Centre de Recherche du CHU de Quebec-Universite Laval, a grant to develop a first-class dual target T cell therapy in bladder cancer, and completing CAD29.46 million financing with Wells Fargo acting as lead underwriter that provided IMV with increased financial flexibility and expansion of our shareholder base.
The DPX-Survivac program continues to be a major value driver for us with a unique mechanism of action, providing significant